Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab

Rituximab is a pioneering anti-CD20 monoclonal antibody that became the first-line drug used in immunotherapy of B-cell malignancies over the last twenty years. Rituximab activates the complement system in vitro, but there is an ongoing debate on the exact role of this effector mechanism in therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Felberg, Anna, Taszner, Michał, Urban, Aleksandra, Majeranowski, Alan, Jaskuła, Kinga, Jurkiewicz, Aleksandra, Stasiłojć, Grzegorz, Blom, Anna M., Zaucha, Jan M., Okrój, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710700/
https://www.ncbi.nlm.nih.gov/pubmed/33329558
http://dx.doi.org/10.3389/fimmu.2020.584509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710700/
https://www.ncbi.nlm.nih.gov/pubmed/33329558
http://dx.doi.org/10.3389/fimmu.2020.584509

Ejemplares similares